The companies plan to combine Nashville's BioVU biobank of 250,000 DNA samples and 2.8 million patient records with GeneWiz's sequencing services.
The move will gain PFM a Houston lab, as well as ApoCell's proprietary ApoStream liquid biopsy technology for isolation and capture of circulating tumor cells.
The assets include significant genetic data related to women's diseases and degenerative disc disease, which Predictive will use to develop gene-based diagnostics.
The firm has been piecing together a collection of acquisitions over recent years that expand its presence in the genomics market, particularly custom oligos.
LGC said that the acquisition will increase its presence in the nucleic acid market, in addition to its previous acquisitions in the last few years.
ACEA's xCELLigence impedance-based, label-free, real-time cell analysis instruments are used in immuno-oncology pre-clinical drug discovery and development.
GeneWiz offers a range of genomic services, including Sanger sequencing, gene synthesis, cloning and mutagenesis, and next-generation sequencing.
Qiagen's partnership and merger agreement with NeuMoDx may help it compete with high-volume molecular testing vendors such as Abbott, Hologic, and Roche.
The deal will join CGI's portfolio of cancer tests and lab services with NovellusDx's technologies for cancer treatment response prediction.
The agreements involve the commercialization of the NeuMoDx 288 and 96 platforms for fully integrated, sample-to-answer, PCR-based molecular diagnostic testing.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.